| Literature DB >> 30863625 |
Xiaodi Qiu1,2,3, Yang Wu4, Yongxiang Jiang1,2,3, Yinghong Ji1,2,3, Xiangjia Zhu1,2,3, Jin Yang1,2,3, Yi Lu1,2,3.
Abstract
Background/Aims. To report a case series of membrane formation on intraocular lenses (IOLs) after uneventful phacoemulsification and to evaluate the material characteristics and biofilm formation on different IOLs. Methods. Ten eyes implanted with the same type of IOLs were found to have membranes on their IOLs after uneventful phacoemulsification from May 2015 to May 2016. No other patients were found with the same phenomenon among 11236 patients who underwent cataract surgeries during this period. To further investigate the reasons for their formation, we assessed seven types of IOLs used in our hospital, including their material characteristics and the presence of microbes (Staphylococcus epidermidis) on the IOL surface by scanning electron microscopy (SEM). All IOLs were incubated under in vitro flow conditions (BioFlux 1000Z). After 36 h, the IOLs were taken from the system, and both the bound bacteria and biofilm formation were observed. Results. Five eyes underwent intravitreal injections of ceftazidime and norvancomycin with one positive culture obtained from the anterior chamber fluid. The other five eyes only received topical treatment of gatifloxacin/levofloxacin and tobramycin. At the last follow-up, all patients had best-corrected visual acuity (BCVA) of 20/50 or better. In the biofilm study on the IOL surface, Staphylococcus epidermidis biofilms formed more readily on hydrophilic acrylic IOLs than on hydrophobic acrylic IOLs. Conclusions. Bacterial adhesion and biofilm tend to develop on certain types of IOLs because of the characteristics of the biomaterial.Entities:
Year: 2019 PMID: 30863625 PMCID: PMC6377987 DOI: 10.1155/2019/5746186
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
The demographics of the ten cases implanted with QUATRIX Aspheric IOLs.
| Case no. | Age | Gender | Medical history | Ophthalmic history | Preoperative VA | Onset (days) | VA on POE | Anterior chamber | Vitreous opacification | AC/vitreous tapping | Tropical treatment | Systemic treatment | Final VA | Final BCVA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 74 | M | — | AMD | 20/100 | 32 | 20/200 | Tyn (+) Cell (+) | Mild | No | Levofloxacin and tobramycin eye drop | Oral levofloxacin | 20/50 | 20/25 |
| 2 | 70 | F | Hypertension | — | 20/200 | 55 | 20/400 | Tyn (++) Cell (++) | Mild to moderate | Yes, (-) | Intravitreal ceftazidime + norvancomycin | Intravenous levofloxacin | 20/80 | 20/40 |
| 3 | 64 | M | — | — | 20/80 | 5 | 20/200 | Tyn (+) Cell (+) | Mild | No | Gatifloxacin and tobramycin eye drop | Intravenous levofloxacin | 20/40 | 20/25 |
| 4 | 74 | F | — | — | 20/100 | 9 | 20/100 | Tyn (+) Cell (+) | Mild | No | Gatifloxacin and tobramycin eye drop | Oral levofloxacin | 20/40 | 20/32 |
| 5 | 76 | F | Hypertension | — | 20/200 | 26 | 20/200 | Tyn (++) Cell (++) | Mild to moderate | Yes, (-) | Intravitreal ceftazidime + norvancomycin | Intravenous levofloxacin | 20/80 | 20/50 |
| 6 | 58 | F | Diabetes | — | 20/200 | 40 | 20/400 | Tyn (+++) Cell (++++) | Mild to moderate | Yes, (-) | YAG + PPV + Intravitreal ceftazidime + norvancomycin | Oral levofloxacin | 20/40 | 20/25 |
| 7 | 67 | F | — | — | 20/100 | 3 | 20/200 | Tyn (+) Cell (+) | Mild to moderate | No | Gatifloxacin and tobramycin eye drop | Oral levofloxacin | 20/50 | 20/32 |
| 8 | 56 | M | — | Pathological myopia | 20/400 | 65 | 20/2000 | Tyn (+++) Cell (++) | Moderate | Yes, | PPV + Intravitreal ceftazidime + norvancomycin | Oral levofloxacin | 20/100 | 20/40 |
| 9 | 74 | F | — | — | 20/80 | 24 | 20/200 | Tyn (+) Cell (+) | Mild to moderate | No | Gatifloxacin eye drop + YAG | Oral levofloxacin | 20/20 | 20/25 |
| 10 | 52 | M | — | Pathological myopia | 20/50 | 16 | 20/400 | Tyn (++) Cell (++) | Mild to moderate | Yes, (-) | Intravitreal ceftazidime + norvancomycin | Oral cefaclor | 20/50 | 20/32 |
AMD = age-related macular degeneration; VA = visual acuity; BCVA = best-corrected visual acuity; PPV = pars plana vitrectomy; YAG = yttrium aluminium garnet.
Intraocular lens characteristics.
| Group | Material | Manufacturer | Model number | Style of haptics | Eyes implanted with the IOL (May 2015–May 2016) |
|---|---|---|---|---|---|
| A | Hydrophilic acrylic | Human Optics AG | MCX11ASP | 1-piece | 998 |
| B | Hydrophilic acrylic (heparin surface modification) | Hexa ision SARL | HQ-201HEP | 1-piece | 51 |
| C | Hydrophilic acrylic | Rayner Intraocular Lenses Limited | 970C | 1-piece | 2279 |
| D | Hydrophilic acrylic | Croma GmbH | QUATRIX Aspheric | 1-piece | 461 |
| E | Hydrophilic acrylic | Croma GmbH | QUATRIX Aspheric Evolutive | 1-piece | NA |
| F | Hydrophobic acrylic | Alcon Laboratories, Inc. | SN60WF | 1-piece | 800 |
| G | Hydrophobic acrylic | Abbott Medical Optics, Inc. | TECNIS ZA9003 | 3-piece | 153 |
Figure 1Slit-lamp images of eyes before and after treatment. (a) Case 4 before treatment. (b) Case 4 after treatment. (c) Case 7 before treatment. (d) Case 7 after treatment. (e) Case 8 before treatment. (f) Case 8 after treatment. (g) Case 9 before treatment. (h) Case 9 after treatment.
Figure 2Scanning electron microscopy of different IOLs. (a) Human Optics MCX11ASP. (b) Hexa Vision HQ-201HEP. (c) Rayner 970C. (d) Croma QUATRIX Aspheric. (e) Croma QUATRIX Aspheric. (f) Croma QUATRIX Aspheric Evolutive. (g) Alcon SN60WF. (h) Abbott TECNIS ZA9003.
Figure 3Scanning electron microscopy of bacterial biofilm on different IOLs. (a) Human Optics MCX11ASP. (b) Hexa Vision HQ-201HEP. (c) Rayner 970C. (d) Croma QUATRIX Aspheric. (e) Croma QUATRIX Aspheric. (f) Croma QUATRIX Aspheric Evolutive. (g) Alcon SN60WF. (h) Abbott TECNIS ZA9003.
Bacterial population enumeration in IOL biofilms (CFU/mm2).
| Group | A | B | C | D | E | F | G |
|---|---|---|---|---|---|---|---|
| 6886 | 132631 | 58670 | 118483 | 76041 | 35368 | 37490 | |
| 8710 | 107873 | 45632 | 86652 | 90189 | 47747 | 31124 | |
| 10524 | 99031 | 40743 | 93726 | 68968 | 33600 | 33423 | |
| Mean ± SD | 8706 ± 1819 | 113178 ± 17416 | 48348 ± 9267 | 99620 ± 16714 | 78399 ± 10805 | 38905 ± 7708 | 34012 ± 3223 |